Rituxan eases arthritis pain
- Share via
Genentech Inc. and Biogen Idec Inc.’s Rituxan helped ease joint pain and inflammation in patients with persistent symptoms of rheumatoid arthritis that required more than one course of treatment, a study found.
The research showed that patients who underwent a second treatment with Rituxan six months after an initial dose had a statistically significant improvement in symptoms compared with those given a placebo the second time.
Genentech, based in South San Francisco, is seeking to expand its current U.S. approval for Rituxan.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
